Product description
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of a larger protective protein (Body Protection Compound, BPC) with a molecular mass of approximately 40,000 Da, which was originally discovered and isolated from human gastric juice.
This peptide is distinguished by remarkable stability – it remains intact in human gastric juice for more than 24 hours, which is an exceptional feature among bioactive peptides. Most standard growth factors (TGF-β, EGF) undergo rapid degradation in the gastric environment, which limits their potential oral applications.
BPC-157 does not exhibit sequence homology with other known peptides, making it a unique compound in the context of tissue regeneration and cytoprotection research.
Mechanism of action
The mechanism of action of BPC-157 is multifaceted and involves interactions with numerous molecular pathways:
Modulation of the nitric oxide (NO) system – BPC-157 interacts with the NO system in a complex manner: it induces nitric oxide release through activation of the Src-caveolin-1-eNOS pathway, while simultaneously modulating both inhibition (via L-NAME) and excessive stimulation (via L-arginine) of nitric oxide synthase. This bidirectional regulation allows restoration of vascular homeostasis.
Activation of the VEGFR2-Akt-eNOS pathway – The peptide activates vascular endothelial growth factor receptor type 2 (VEGFR2), which leads to stimulation of angiogenesis without the need for other ligands or shear stress.
Effect on the growth hormone receptor – Studies in rat tendon fibroblasts have shown that BPC-157 increases growth hormone receptor (GHR) expression, which may contribute to regenerative effects in connective tissues.
Interaction with the gut-brain axis – As a gastric-derived peptide, BPC-157 fits into the concept of the gut-brain axis, where peptides native to the digestive tract may exert both peripheral and central effects. The peptide influences the serotonergic and dopaminergic systems in specific brain regions.
Cytoprotective action – BPC-157 functions as a cell membrane stabilizer (counteracting leaky gut syndrome) and free radical scavenger, protecting cells against oxidative stress.
Scientific research directions
BPC-157 is the subject of intensive preclinical research, mainly in animal models. A 2025 systematic review identified 36 studies published between 1993 and 2024, of which 35 were preclinical studies.
Research on tendon healing
One of the most intensively studied areas is the effect of BPC-157 on tendon regeneration. In models of transected Achilles tendon in rats, BPC-157 accelerated tendon explant outgrowth, increased tendon fibroblast migration, and improved cell survival under oxidative stress (H₂O₂). Biomechanical studies showed increased tensile strength, Young's modulus, and improved functional gait parameters.
Research on muscle regeneration
In models of muscle injury (quadriceps transection, calf muscle injury), BPC-157 stimulated early collagen organization, egr-1 gene expression, and the nab2 repressor, leading to faster healing. The peptide also demonstrated the ability to restore blood flow in ischemic muscles through stimulation of angiogenesis.
Research on ligaments and bones
Preclinical studies also include models of ligament damage and bone fractures. BPC-157 improved the structural and biomechanical parameters of healing tissues, although the molecular mechanisms require further clarification.
Gastroenterology research
Due to its gastric origin, BPC-157 is being intensively studied in the context of gastrointestinal mucosal protection. The peptide showed anti-ulcer activity in models of damage induced by stress, ethanol, indomethacin, and capsaicin. Clinical studies have been conducted in inflammatory bowel disease (IBD), although the full results have not yet been published.
Research on the cardiovascular system
BPC-157 is being studied for protection of the heart against injury, anti-arrhythmic effects, and modulation of thrombosis. In models of large vessel occlusion, the peptide activated collateral circulation pathways, counteracting multi-organ failure.
Neurological research
In the context of the gut-brain axis, BPC-157 is being studied for anxiolytic, antidepressant, anticonvulsant effects and for counteracting catalepsy symptoms and schizophrenia-like models in rats. The peptide influenced serotonin release in specific brain regions, mainly in the nigrostriatal system.
Research on spinal cord injuries
Preliminary preclinical studies are analyzing the potential of BPC-157 in reducing inflammation and supporting nerve regeneration after compressive spinal cord injuries.
Scientific context
BPC-157 fits into the concept of gastric cytoprotection proposed by André Robert, according to which peptides native to the digestive tract can exert a broad range of protective effects on various organs. This is consistent with the observation that compounds with strong anti-ulcer activity often also show beneficial effects in other tissues.
Compared with other regenerative peptides (such as TB-500/Thymosin β4 or collagen peptides), BPC-157 stands out for:
- Stability in the gastric environment
- No need for carriers
- Effectiveness with both local and systemic administration
- Activity at very low doses (range from ng/kg to µg/kg)
Regulatory status and safety
In 2023, the FDA classified BPC-157 as a category 2 substance, which means it cannot be compounded by commercial pharmaceutical companies due to insufficient human safety data.
In the available preclinical studies, no significant toxic effects were reported across a wide dose range. In the only published pilot clinical study (2025), intravenous administration of BPC-157 up to 20 mg was well tolerated, with no significant changes in vital signs, ECG, or laboratory markers of cardiac, liver, kidney, and thyroid function.
However, the long-term safety profile in humans remains unknown due to the limited number of clinical studies.
Bibliography – latest scientific research
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Orthop J Sports Med. 2025;13(6). PMC
- Liao HJ, Chen HT, Chang CH. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC
- Walczak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. MDPI
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain–Gut Axis and Gut–Brain Axis Function. Pharmaceuticals. 2023;16(5):676. PMC
- Kang EA, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMC
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. PMC
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153-167. PMC
- Madzarac G, Vlainic J, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2017;15(6):857-865. PMC
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ScienceDirect
